Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 12:12 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 13,760 matching trials from the live ClinicalTrials.gov search.
Conditions
Renal Cell Carcinoma
Interventions
Nivolumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
39
States / cities
Phoenix, Arizona • Bakersfield, California • Fullerton, California + 35 more
Conditions
T-cell Lymphomas, T-cell Leukemia, Sezary Syndrome, Mycosis Fungoides, Cutaneous T-cell Lymphoma (CTCL)
Interventions
A-dmDT390-bisFv(UCHT1)
Biological
Lead sponsor
Virogen Biotechnology Inc.
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
5
States / cities
New Haven, Connecticut • Louisville, Kentucky • Dallas, Texas + 2 more
Conditions
COVID-19
Interventions
Treatment for COVID-19
Other
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older
Enrollment
550 participants
Timeline
2020 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Moderate to Severe Atopic Dermatitis
Interventions
Dilute bleach baths, Water
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
2 Years to 17 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Heart Failure, Left Ventricular Systolic Dysfunction
Interventions
Vericiguat tablet, Vericiguat suspension, Placebo tablet, Placebo suspension
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
29 Days to 17 Years
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
20
States / cities
Los Angeles, California • Palo Alto, California • San Bernardino, California + 17 more
Conditions
Alzheimer Disease
Interventions
bapineuzumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 89 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
16
States / cities
Phoenix, Arizona • Encino, California • Delray Beach, Florida + 11 more
Conditions
Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts, Myelodysplastic Syndrome With Excess Blasts-1, Myelodysplastic Syndrome/Acute Myeloid Leukemia
Interventions
Azacitidine, Laboratory Biomarker Analysis, Lenalidomide, Vorinostat
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
280
States / cities
Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 217 more
Conditions
Acute, Uncomplicated Human Influenza
Interventions
Peramivir, Placebo
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
67
States / cities
Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 58 more
Conditions
Cancer, Breast Cancer
Interventions
Ixabepilone + Capecitabine, Capecitabine
Drug
Lead sponsor
R-Pharm
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
34
States / cities
Tucson, Arizona • Beverly Hills, California • Corona, California + 31 more
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec, placebo, liraglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
67
States / cities
Anaheim, California • Concord, California • Escondido, California + 59 more
Conditions
Influenza
Interventions
MF59-eH1N1_f
Biological
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
2,719 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
20
States / cities
Miami, Florida • Lenexa, Kansas • Omaha, Nebraska + 16 more
Conditions
Diarrhea-predominant Irritable Bowel Syndrome
Interventions
BOS-589, Placebo
Drug
Lead sponsor
Boston Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
58
States / cities
Anniston, Alabama • Huntsville, Alabama • Chandler, Arizona + 48 more
Conditions
Solid Tumor
Interventions
ASP1012, Pembrolizumab
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
8
States / cities
Los Angeles, California • Newport Beach, California • Atlanta, Georgia + 5 more
Conditions
Healthy Volunteers (Meningococcal Infection)
Interventions
MenACYW conjugate vaccine, MenACYW-135 conjugate vaccine, DTaP-IPV//Hib vaccine, Pneumococcal 13-valent conjugate vaccine, Pentavalent rotavirus vaccine, Hepatitis B vaccine, Measles, mumps, rubella (MMR) vaccine, Varicella vaccine, Hepatitis A vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
42 Days to 89 Days
Enrollment
2,627 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
65
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 54 more
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Neuromuscular Blockade in Patients With Severe Renal Impairment

NCT03904550
Conditions
Neuromuscular Blockade, Renal Impairment
Interventions
Cisatracurium + Neostigmine, Rocuronium + Sugammadex
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Type 1 Diabetes Mellitus
Interventions
HOE901-U300 (Insulin Glargine 300 U/ml), Lantus (Insulin Glargine 100 U/ml), Mandated back ground therapy
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years
Enrollment
638 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
99
States / cities
Little Rock, Arkansas • Concord, California • Escondido, California + 80 more
Conditions
Hepatocellular Carcinoma
Interventions
Tremelimumab, Durvalumab, Bevacizumab
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
433 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
16
States / cities
Phoenix, Arizona • San Francisco, California • New Haven, Connecticut + 12 more
Conditions
Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant, Lung Transplant Rejection, Lung Transplant; Complications, Lung Transplant Failure and Rejection, Chronic Lung Allograft Dysfunction
Interventions
Liposomal Cyclosporine A, Standard of Care
Drug
Lead sponsor
Zambon SpA
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
21
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 16 more
Conditions
Hepatitis C, Chronic
Interventions
GS-5885, GS-9451, tegobuvir, placebo to match tegobuvir, placebo to match RBV, Ribavirin
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
37
States / cities
Tucson, Arizona • Anaheim, California • Beverly Hills, California + 30 more
Terminated Phase 1Phase 2 Interventional Results available

Siplizumab in T1DM

NCT05574335
Conditions
Type 1 Diabetes Mellitus
Interventions
Siplizumab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
8 Years to 45 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
5
States / cities
Aurora, Colorado • Iowa City, Iowa • New York, New York + 2 more
Completed Not applicable Interventional Accepts healthy volunteers

Ice Application for Postoperative Pain

NCT04145791
Conditions
Postoperative Pain
Interventions
Ice
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
2
States / cities
Dallas, Texas
Conditions
Generalized Anxiety Disorder
Interventions
Placebo, Vortioxetine, Duloxetine
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
781 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
66
States / cities
Anaheim, California • Beverly Hills, California • Fresno, California + 63 more
Conditions
Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, Systemic Sclerosis, Rheumatoid Arthritis
Interventions
CC-97540, Fludarabine, Cyclophosphamide, Tocilizumab
Drug
Lead sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
25
States / cities
Aurora, Colorado • Denver, Colorado • Jacksonville, Florida + 16 more
Completed No phase listed Observational Accepts healthy volunteers

Study to Evaluate MEDI-534 in Healthy Adults

NCT00111878
Conditions
Respiratory Syncytial Virus Infections, Parainfluenza Infections
Interventions
MEDI-534
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 40 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
3
States / cities
Columbus, Ohio • Pittsburgh, Pennsylvania • Dallas, Texas